Nyrada Inc (ASX: NYR) - Share Price
Current share price for NYR : $0.740 0.015 (2.07%)+
Nyrada Inc (NYR) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a clinical-stage biotechnology company focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels.
NYR General Information +
| ASX Code | NYR |
| Website | http://www.nyrada.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 183 |
| NYR Share Price | $0.740 |
| Day High | $0.755 |
| Day Low | $0.705 |
| Last Close | $0.725 |
| NYR Share Price Movement | $0.02 ( 2.07% ) |
Prices as at 16:40, 7 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Nyrada Inc (NYR) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Nyrada Inc (NYR) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Nyrada Inc (NYR) price-sensitive announcements
NYR - Xolatryp Demonstrates Cardioprotection in Preclinical Study
Nyrada Inc conducted a preclinical study to evaluate the efficacy of their drug Xolatryp i
Nyrada Inc (NYR)
21 Aug 2026 | 8:50 AM
21 Aug 2026 | 8:50 AM
NYR - Preliminary Final Report
Nyrada Inc.'s preliminary final report for the year ending 30 June 2026 shows a 14% declin
Nyrada Inc (NYR)
18 Aug 2026 | 1:05 PM
18 Aug 2026 | 1:05 PM
NYR - Quarterly Activities Report and Appendix 4C
Nyrada Inc, a clinical-stage biotechnology company, released its Quarterly Activities Repo
Nyrada Inc (NYR)
27 Jul 2026 | 8:44 AM
27 Jul 2026 | 8:44 AM
NYR - Response to ASX Price Query
Nyrada Inc., a biotechnology company focused on developing therapies targeting TRPC ion ch
Nyrada Inc (NYR)
15 Jul 2026 | 4:58 PM
15 Jul 2026 | 4:58 PM
Nyrada Inc (NYR) Recent ASX Announcements
NYR Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$6.56 | -$2.70 | 13.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$4.85 | -$2.40 | 184.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$1.39 | -$0.90 | -83.00% | 0.00 | 0.00 | 0.00% | 0.0% |
NYR Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $847M | 0.4454 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,608M | -0.7857 | 0.2462 | 0.9655 | 88.3971 | 70.9310 | 36.0877 | 0.00% | 1.60% | 1.90% |
| Nyrada Inc (NYR) | $178M | 0.1322 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
NYR Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 18.80 | 0.00 |
| Market | 0.35 | 13.60 | 1.17 | 0.81 |
| Sector | 0.66 | 31.20 | 3.01 | 2.67 |
NYR Directors
| Name | Position | Start Date |
|---|---|---|
| Mr James Bonnar | Chief Executive Officer, Managing Director | 8 Oct 2025 |
| Dr Ian Edward Dixon | Founder, Non-Executive Director | 8 Sep 2020 |
| Mr John Alexander Moore | Non-Executive Chairman, Non-Executive Director | 4 Jun 2019 |
| Mr Ruediger Weseloh | Non-Executive Director | 4 Jun 2019 |
| Mr Christopher Cox | Non-Executive Director | 7 Nov 2019 |
| Mr Marcus Frampton | Non-Executive Director | 4 Jun 2019 |
Nyrada Inc (NYR) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 11 Jun 2026 | BONNAR, James | Buy | Indirect Shares | 4,400 | $0.470 | $2,068.000 |
| 11 Jun 2026 | BONNAR, James | Buy | Indirect Shares | 7,000 | $0.460 | $3,220.000 |
| 10 Jun 2026 | BONNAR, James | Buy | Indirect Shares | 6,000 | $0.480 | $2,880.000 |
See all changes in directors' interest & trades for Nyrada Inc (NYR) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
NYR Management
| Name | Position |
|---|---|
| David James Franks | Company Secretary |
NYR Calendar of Events
| Date | Event |
|---|---|
| 17 August 2027 | Report (Annual) |
| 17 August 2027 | Report (Prelim) |
| 17 February 2027 | Report (Interim) |
| 10 November 2026 | AGM |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
